FDA tentatively approves bone cancer generic

ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to a generic version of a bone cancer drug, FDA records showed.

The FDA’s decision will allow Hospira to begin marketing its zoledronic acid injection, a generic version of Novartis’ Zometa, after the patent expires, in September 2012.

Zometa had sales of $1.47 billion in 2009, according to Novartis financial data.

Login or Register to post a comment.